skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Profound thrombocytopenia after primary exposure to eptifibatide

Case report

(1578) Views  (337) Full article downloads

Authors: Nicholas B Norgard, Brian T Badgley

Published Date September 2010 Volume 2010:2 Pages 163 - 167
DOI: http://dx.doi.org/10.2147/DHPS.S13239

Nicholas B Norgard, Brian T Badgley
University at Buffalo, School of Pharmacy and Pharmaceutical Sciences, Buffalo, NY, USA

Abstract: Eptifibatide is a glycoprotein IIb/IIIa receptor antagonist used to reduce the incidence of ischemic events in patients with acute coronary syndromes and those undergoing percutaneous coronary intervention. A minority of patients given eptifibatide develop acute, profound thrombocytopenia (<20,000 cells/mm3) within a few hours of receiving the drug. This case report discusses a patient who developed profound thrombocytopenia within hours of receiving eptifibatide for the first time. The Naranjo algorithm classified the likelihood that this patient’s thrombocytopenia was related to eptifibatide as probable. Profound thrombocytopenia is an uncommon but clinically important complication of eptifibatide. This case report emphasizes the importance of monitoring platelet counts routinely at baseline and within 2–6 hours of eptifibatide administration.

Keywords: drug-induced thrombocytopenia, glycoprotein IIb/IIIa antagonists, eptifibatide, thrombocytopenia




 

Other articles by Dr Nicholas Norgard



Readers of this article also read:

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Exacerbation rate, health status and mortality in COPD – a review of potential interventions
Anesthesiologists’ perception of patients’ anxiety under regional anesthesia
Phosphodiesterase-5 inhibitors in management of pulmonary hypertension: Safety, tolerability, and efficacy
Improvement of adenoviral vector-mediated gene transfer to airway epithelia by folate-modified anionic liposomes
Perception of risk and benefit in patient-centered communication and care
The relationship between deliberate self-harm behavior, body dissatisfaction, and suicide in adolescents: current concepts
Zinc oxide nanoparticles as selective killers of proliferating cells
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy
Evaluation of analgesic efficacy of bromfenac sodium ophthalmic solution 0.09% versus ketorolac tromethamine ophthalmic solution 0.5% following LASEK or Epi-LASIK
  • Testimonials

    "You do a tremendous job!!" Ruben Restrepo, The University of Texas Health Science Center at San Antonio